Anavex life sciences announces issuance of blarcamesine (anavex®2-73) composition of matter u.s. patent expanding its intellectual property portfolio

New york, jan. 27, 2025 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, announced today it was issued a new u.s. patent no. 12,180,174 entitled “a2-73 crystalline polymorph compositions of matter and methods of use thereof” from the united states patent and trademark office (uspto) for its u.s. patent application serial number ussn: 17/978,818.
AVXL Ratings Summary
AVXL Quant Ranking